Payment overview · 2025
General Payments
$61.81
3 reported records · 3 companies
Healthcare provider profile · identity verified
Michael Cooper, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLAREMORE, OK · NPI 1336109727
Verified facts
What the public records show
CMS Open Payments records show Michael Cooper, D.O. received $61.81 in general payments during 2025 across 3 reported records.
Astellas Pharma US Inc accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.90 | 40.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.30 | 32.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.61 | 26.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 377 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 68 |
| Omeprazole | Omeprazole | 274 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 269 | 81 |
| Trazodone Hcl | Trazodone Hcl | 220 | 60 |
| Gabapentin | Gabapentin | 197 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 167 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 163 | 25 |
| Losartan Potassium | Losartan Potassium | 156 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 123 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | 38 |
| Metformin Hcl | Metformin Hcl | 118 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 39 |
| Potassium Chloride | Potassium Chloride | 109 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 32 |
| Morphine Sulfate Er | Morphine Sulfate | 104 | suppressed |
| Furosemide | Furosemide | 100 | 29 |
| Meloxicam | Meloxicam | 100 | 32 |
| Eliquis | Apixaban | 99 | 17 |
| Sertraline Hcl | Sertraline Hcl | 99 | 28 |
| Clonazepam | Clonazepam | 94 | 14 |
| Simvastatin | Simvastatin | 88 | 17 |
| Pregabalin | Pregabalin | 87 | 17 |
| Spironolactone | Spironolactone | 87 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 28 |
| Montelukast Sodium | Montelukast Sodium | 74 | 17 |
| Ozempic | Semaglutide | 74 | 14 |
| Jardiance | Empagliflozin | 73 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 22 |
| Metformin Hcl Er | Metformin Hcl | 71 | 23 |
| Bupropion Xl | Bupropion Hcl | 70 | 20 |
| Morphine Sulfate | Morphine Sulfate | 68 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 66 | suppressed |
| Mirtazapine | Mirtazapine | 66 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 15 |
| Carvedilol | Carvedilol | 62 | 17 |
| Naproxen | Naproxen | 62 | 15 |
| Januvia | Sitagliptin Phosphate | 61 | 12 |
| Tradjenta | Linagliptin | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 59 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Lovastatin | Lovastatin | 56 | 15 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 14 |
| Famotidine | Famotidine | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 16 |
| Xtampza Er | Oxycodone Myristate | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Atenolol | Atenolol | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 13 |
| Linzess | Linaclotide | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Alprazolam Xr | Alprazolam | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.81 · 3 records | Astellas Pharma US Inc | GEMTESA, Ozempic, Rybelsus, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error